142 related articles for article (PubMed ID: 9484360)
1. Estimation of the temporal probability of human immunodeficiency virus (HIV) dementia after risk stratification for HIV-infected persons.
Qureshi AI; Hanson DL; Jones JL; Janssen RS
Neurology; 1998 Feb; 50(2):392-7. PubMed ID: 9484360
[TBL] [Abstract][Full Text] [Related]
2. Epidemiology of anemia in human immunodeficiency virus (HIV)-infected persons: results from the multistate adult and adolescent spectrum of HIV disease surveillance project.
Sullivan PS; Hanson DL; Chu SY; Jones JL; Ward JW
Blood; 1998 Jan; 91(1):301-8. PubMed ID: 9414298
[TBL] [Abstract][Full Text] [Related]
3. Ten-year trends in CD4 cell counts at HIV and AIDS diagnosis in a London HIV clinic.
Easterbrook PJ; Yu LM; Goetghebeur E; Boag F; McLean K; Gazzard B
AIDS; 2000 Mar; 14(5):561-71. PubMed ID: 10780719
[TBL] [Abstract][Full Text] [Related]
4. Clinical and behavioral characteristics of adults receiving medical care for HIV infection --- Medical Monitoring Project, United States, 2007.
Blair JM; McNaghten AD; Frazier EL; Skarbinski J; Huang P; Heffelfinger JD
MMWR Surveill Summ; 2011 Sep; 60(11):1-20. PubMed ID: 21881551
[TBL] [Abstract][Full Text] [Related]
5. Immunologic markers of AIDS progression: consistency across five HIV-infected cohorts. Multicohort Analysis Project Workshop. Part I.
AIDS; 1994 Jul; 8(7):911-21. PubMed ID: 7946100
[TBL] [Abstract][Full Text] [Related]
6. Psychosocial risk factors of HIV morbidity and mortality: findings from the Multicenter AIDS Cohort Study (MACS).
Farinpour R; Miller EN; Satz P; Selnes OA; Cohen BA; Becker JT; Skolasky RL; Visscher BR
J Clin Exp Neuropsychol; 2003 Aug; 25(5):654-70. PubMed ID: 12815503
[TBL] [Abstract][Full Text] [Related]
7. Meta-analysis of five randomized controlled trials comparing continuation of zidovudine versus switching to didanosine in HIV-infected individuals.
Raboud JM; Montaner JS; Rae S; Kahn J; Hammer SM; Katzenstein DA; Pavia A; Dolin R; Hughes MD; Cross A; Beltangady M; Gatell J; Dunkle L; Smaldone L
Antivir Ther; 1997 Dec; 2(4):237-47. PubMed ID: 11327443
[TBL] [Abstract][Full Text] [Related]
8. Incidence and natural history of Mycobacterium avium-complex infections in patients with advanced human immunodeficiency virus disease treated with zidovudine. The Zidovudine Epidemiology Study Group.
Chaisson RE; Moore RD; Richman DD; Keruly J; Creagh T
Am Rev Respir Dis; 1992 Aug; 146(2):285-9. PubMed ID: 1362634
[TBL] [Abstract][Full Text] [Related]
9. Spectrum of disease in persons with human immunodeficiency virus infection in the United States.
Farizo KM; Buehler JW; Chamberland ME; Whyte BM; Froelicher ES; Hopkins SG; Reed CM; Mokotoff ED; Cohn DL; Troxler S
JAMA; 1992 Apr; 267(13):1798-805. PubMed ID: 1347573
[TBL] [Abstract][Full Text] [Related]
10. Behavioral and clinical characteristics of persons receiving medical care for HIV infection - Medical Monitoring Project, United States, 2009.
Blair JM; Fagan JL; Frazier EL; Do A; Bradley H; Valverde EE; McNaghten A; Beer L; Zhang S; Huang P; Mattson CL; Freedman MS; Johnson CH; Sanders CC; Spruit-McGoff KE; Heffelfinger JD; Skarbinski J;
MMWR Suppl; 2014 Jun; 63(5):1-22. PubMed ID: 24941443
[TBL] [Abstract][Full Text] [Related]
11. The impact of zidovudine on dementia-free survival in a population of HIV-positive men and women on antiretroviral therapy.
Cornelisse PG; Montessori V; Yip B; Craib KJ; O'Shaughnessy MV; Montaner JS; Hogg RS
Int J STD AIDS; 2000 Jan; 11(1):52-6. PubMed ID: 10667902
[TBL] [Abstract][Full Text] [Related]
12. Changes in the incidence and predictors of human immunodeficiency virus-associated dementia in the era of highly active antiretroviral therapy.
Bhaskaran K; Mussini C; Antinori A; Walker AS; Dorrucci M; Sabin C; Phillips A; Porter K;
Ann Neurol; 2008 Feb; 63(2):213-21. PubMed ID: 17894380
[TBL] [Abstract][Full Text] [Related]
13. Mortality in an urban cohort of HIV-infected and at-risk drug users in the era of highly active antiretroviral therapy.
Kohli R; Lo Y; Howard AA; Buono D; Floris-Moore M; Klein RS; Schoenbaum EE
Clin Infect Dis; 2005 Sep; 41(6):864-72. PubMed ID: 16107987
[TBL] [Abstract][Full Text] [Related]
14. Surveillance for thrombocytopenia in persons infected with HIV: results from the multistate Adult and Adolescent Spectrum of Disease Project.
Sullivan PS; Hanson DL; Chu SY; Jones JL; Ciesielski CA
J Acquir Immune Defic Syndr Hum Retrovirol; 1997 Apr; 14(4):374-9. PubMed ID: 9111481
[TBL] [Abstract][Full Text] [Related]
15. Natural history of advanced HIV disease in patients treated with zidovudine. The Zidovudine Epidemiology Study Group.
Moore RD; Keruly J; Richman DD; Creagh-Kirk T; Chaisson RE
AIDS; 1992 Jul; 6(7):671-7. PubMed ID: 1503686
[TBL] [Abstract][Full Text] [Related]
16. Prognostic factors in human immunodeficiency virus-positive patients with a CD4+ lymphocyte count < 50/microL.
Apolonio EG; Hoover DR; He Y; Saah AJ; Lyter DW; Detels R; Kaslow RA; Phair JP
J Infect Dis; 1995 Apr; 171(4):829-36. PubMed ID: 7706809
[TBL] [Abstract][Full Text] [Related]
17. Projections of the number of persons diagnosed with AIDS and the number of immunosuppressed HIV-infected persons--United States, 1992-1994.
Karon JM; Buehler JW; Byers RH; Farizo KM; Green TA; Hanson DL; Rosenblum LS; Gail MH; Rosenberg PS; Brookmeyer R
MMWR Recomm Rep; 1992 Dec; 41(RR-18):1-29. PubMed ID: 1480128
[TBL] [Abstract][Full Text] [Related]
18. Zidovudine in asymptomatic human immunodeficiency virus infection. A controlled trial in persons with fewer than 500 CD4-positive cells per cubic millimeter. The AIDS Clinical Trials Group of the National Institute of Allergy and Infectious Diseases.
Volberding PA; Lagakos SW; Koch MA; Pettinelli C; Myers MW; Booth DK; Balfour HH; Reichman RC; Bartlett JA; Hirsch MS
N Engl J Med; 1990 Apr; 322(14):941-9. PubMed ID: 1969115
[TBL] [Abstract][Full Text] [Related]
19. Predictors of symptomatic HIV-associated neurocognitive disorders in universal health care.
McCombe JA; Vivithanaporn P; Gill MJ; Power C
HIV Med; 2013 Feb; 14(2):99-107. PubMed ID: 22994556
[TBL] [Abstract][Full Text] [Related]
20. Characteristics, determinants, and clinical relevance of CD4 T cell recovery to <500 cells/microL in HIV type 1-infected individuals receiving potent antiretroviral therapy.
Kaufmann GR; Furrer H; Ledergerber B; Perrin L; Opravil M; Vernazza P; Cavassini M; Bernasconi E; Rickenbach M; Hirschel B; Battegay M;
Clin Infect Dis; 2005 Aug; 41(3):361-72. PubMed ID: 16007534
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
